• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by ENvue Medical Inc.

    3/31/26 4:05:18 PM ET
    $FEED
    Industrial Specialties
    Health Care
    Get the next $FEED alert in real time by email
    NT 10-K 1 formnt10-k.htm NT 10-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10D ☐ Form N-CEN
      ☐ Form N-CSR
      For Period Ended: December 31, 2025
       
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      For the Transition Period Ended:______________________________________________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I – REGISTRANT INFORMATION

     

    ENvue Medical, Inc.

    Full Name of Registrant

     

    Former Name if Applicable

     

    969 Pruitt Ave

    Address of Principal Executive Office (Street and Number)

     

    Tyler, Texas 77569

    City, State and Zip Code

     

     

     

     

     

     

    PART II – RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III – NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    ENvue Medical, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) within the time period, as the Company requires additional time to review the information required to be included in the Form 10-K, including the financial statements, for the fourth quarter and fiscal year ended December 31, 2025.

     

    The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended.

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Doron Besser, M.D.

      (914)   233-3004
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
      Yes ☒ No ☐
       

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

    Yes ☐ No ☒

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    NanoVibronix, Inc.

    (Name of registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date:

    March 31, 2026

      By: /s/ Doron Besser
          Name:

    Doron Besser, M.D.

          Title: Chief Executive Officer

     

    ATTENTION

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $FEED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEED

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FEED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fernandez-Mcgovern Nicole M.

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    2/26/26 7:46:18 PM ET
    $FEED
    Industrial Specialties
    Health Care

    New insider Glibert Christian Michael claimed ownership of 240,000 shares (SEC Form 3)

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    2/11/26 7:00:21 PM ET
    $FEED
    Industrial Specialties
    Health Care

    Large owner Glibert Christian Michael bought $640,800 worth of shares (240,000 units at $2.67) (SEC Form 4)

    4 - ENvue Medical, Inc. (0001326706) (Issuer)

    2/11/26 6:52:48 PM ET
    $FEED
    Industrial Specialties
    Health Care

    $FEED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glibert Christian Michael bought $640,800 worth of shares (240,000 units at $2.67) (SEC Form 4)

    4 - ENvue Medical, Inc. (0001326706) (Issuer)

    2/11/26 6:52:48 PM ET
    $FEED
    Industrial Specialties
    Health Care

    $FEED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39

    TYLER, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced a purchase of the ENvue™ Navigation Platform and feeding tubes by a premier teaching hospital and Level I Trauma Center serving the Detroit metropolitan area. The purchase expands ENvue's presence within a major Southeast Michigan health system where the Company has previously been deployed, and brings ENvue's U.S. hospital footprint to 39 hospitals. The facility is a 714-bed major teaching ho

    3/24/26 8:07:00 AM ET
    $FEED
    Industrial Specialties
    Health Care

    ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera

    TYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue," "ENvue Medical" or the "Company"), a leader in advanced navigation technologies for enteral access, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's patent application titled "Feeding Tube with Electromagnetic Sensor and Camera," Application No. 18/199,059. The allowed patent includes 18 claims covering a feeding tube design that combines electromagnetic navigation with an integrated distal-tip camera, enabling both positional guidance and direct visualization during placement. The allowed claims include innovations such

    2/24/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line

    TYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the signing of a distribution agreement with U-Deliver to distribute ENvue's recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels. "We believe that our partnership with U-Deliver is an important step in scaling ENvue's over-the-counter ENFit syringe line and strengthening our presence in the non-acute enteral care marke

    1/28/26 9:00:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    $FEED
    SEC Filings

    View All

    SEC Form NT 10-K filed by ENvue Medical Inc.

    NT 10-K - ENvue Medical, Inc. (0001326706) (Filer)

    3/31/26 4:05:18 PM ET
    $FEED
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ENvue Medical Inc.

    SCHEDULE 13G/A - ENvue Medical, Inc. (0001326706) (Subject)

    3/6/26 1:27:52 PM ET
    $FEED
    Industrial Specialties
    Health Care

    SEC Form SCHEDULE 13G filed by ENvue Medical Inc.

    SCHEDULE 13G - ENvue Medical, Inc. (0001326706) (Subject)

    2/6/26 4:54:54 PM ET
    $FEED
    Industrial Specialties
    Health Care

    $FEED
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties